Ankit Mahadevia
2017
In 2017, Ankit Mahadevia earned a total compensation of $3.2M as Chief Executive Officer at Spero Therapeutics, a 291% increase compared to previous year.
Compensation breakdown
Bonus | $114,000 |
---|---|
Option Awards | $2,679,616 |
Salary | $389,574 |
Other | $1,087 |
Total | $3,184,277 |
Mahadevia received $2.7M in option awards, accounting for 84% of the total pay in 2017.
Mahadevia also received $114K in bonus, $389.6K in salary and $1.1K in other compensation.
Rankings
In 2017, Ankit Mahadevia's compensation ranked 3,376th out of 14,666 executives tracked by ExecPay. In other words, Mahadevia earned more than 77.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,376 | 77th |
Manufacturing | 1,158 | 80th |
Chemicals And Allied Products | 318 | 85th |
Drugs | 244 | 86th |
Pharmaceutical Preparations | 193 | 86th |
Mahadevia's colleagues
We found three more compensation records of executives who worked with Ankit Mahadevia at Spero Therapeutics in 2017.
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019